OCUGEN, INC. Contract with Customer, Liability, Noncurrent
OCUGEN, INC. (OCGN) had Contract with Customer, Liability, Noncurrent of $800.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-03-04
- 2025-12-31: Contract with Customer, Liability, Noncurrent $800.00K.
- 2019-06-30: Contract with Customer, Liability, Noncurrent $10.00M.
- 2019-03-31: Contract with Customer, Liability, Noncurrent $10.00M.
- 2018-12-31: Contract with Customer, Liability, Noncurrent $10.00M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2025-12-31 | $800.00K 10-K · filed 2026-03-04 |
| 2019-06-30 | $10.00M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $10.00M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $10.00M 10-Q · filed 2019-08-09 |
| 2018-09-30 | $5.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $2.50M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |